FDA reaches vague conclusion in debate over safety of paclitaxel devices - Cardiovascular Business

FDA reaches vague conclusion in debate over safety of paclitaxel devices  Cardiovascular Business

Two days of debate over the safety of paclitaxel-coated and -eluting devices have culminated in a nonbinding recommendation by the FDA to continue sales of ...